Open an account

Rhythm Pharmaceuticals

RYTM · NASDAQ

$90.20+$1.97 (+2.23%)TodayMarket closed ·
Prev close $88.23

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The company is headquartered in Boston, Massachusetts and currently employs 414 full-time employees. The company went IPO on 2017-10-05. The firm's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.

Employees
414
Headquarters
Boston, Massachusetts
Listed
Oct 5, 2017
Sector
Health Care
Industry
Biotechnology
Website
rhythmtx.com

RYTM key statistics

Market cap
6.21B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
741.48K
Volume
877.03K
Open price
$88.56
High today
$91.88
Low today
$88.56
52 Week high
$122.20
52 Week low
$74.50

Rhythm Pharmaceuticals (RYTM) at a glance

As of Oct 20, 2026, Rhythm Pharmaceuticals (RYTM) shares are priced at $90.20, giving the company a market cap of 6.21B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $88.56 and $91.88. The current price is 1.9% above the day's low and 1.8% below its high.

Volume so far is 877.03K shares, in line with the average of 741.48K shares a day.

Over the past year Rhythm Pharmaceuticals has ranged from $74.50 to $122.20, and now sits 33% of the way up that range.

Rhythm Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.73 per share against an estimate of -$0.8376.

The average analyst price target is $140.89, 56.2% above the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

93%of 15 analyst ratings say Buy
  • Buy93.3%
  • Hold6.7%
  • Sell0.0%
Price target · 19 analystsAvg $140.89
Low
$106.05
Now
$90.20
High
$168.00

RYTM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 8.4% on average.

  1. Q3 FY24: reported -$0.73 per share against an estimate of -$0.8208
  2. Q4 FY24: reported -$0.72 per share against an estimate of -$0.7255
  3. Q1 FY25: reported -$0.81 per share against an estimate of -$0.7157
  4. Q2 FY25: reported -$0.75 per share against an estimate of -$0.6891
  5. Q3 FY25: reported -$0.82 per share against an estimate of -$0.7384
  6. Q4 FY25: reported -$0.73 per share against an estimate of -$0.838
  7. Q1 FY26: reported -$0.83 per share against an estimate of -$0.8697
  8. Q2 FY26: reported -$0.73 per share against an estimate of -$0.8376

RYTM news

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Vandana Singh

    Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

  • Vandana Singh

    Why Is Rhythm Pharma Stock Jumping Today?

  • Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call

  • Press releasePRNewswire

    PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

  • Vandana Singh

    Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy

Similar companies

Companies in the same industry as Rhythm Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.